Examining convalescent plasma transfusion in severe COVID-19 patients, recent research highlights the significance of S-RBD antibodies and IL-10 levels
Downloads
Convalescent plasma (CP) may be an option for people with severe COVID-19. However, its efficiency remains unknown. A study was done to determine whether the levels of Anti-SARS-CoV-2 Spike Receptor-Binding Domain (S-RBD) antibodies and IL-10 in COVID-19 patients who had CP transfusion were related to their survival status. The observational cohort study included 40 patients with severe COVID-19 who were followed for 28 days after receiving a CP transfusion. Antibody and IL-10 levels were assessed on Day 1 before to CP transfusion and on Days 1, 2, and 7 following CP transfusion. Twenty six (65%) of the 40 patients survived. Anti-SARS-CoV-2 S-RBD antibody levels were observed to be significantly higher on Days 1, 2, and 7 following CP transfusion (p-value 0.05). Furthermore, IL-10 levels dropped significantly on Days 2 and 7 (p-value 0.05). However, neither the CT value nor the patients' survival status were linked to greater antibody levels or changes in IL-10 levels. According to the findings, CP transfusion can greatly enhance anti-SARS-CoV-2 S-RBD antibody levels while drastically decreasing IL-10 levels. These findings may have therapeutic implications for the use of CP as a COVID-19 therapy option. More research is needed to determine its efficacy in enhancing the survival rate of COVID-19 patients with severe symptoms.
WHO Indonesia. Coronavirus Disease Coronavirus Disease Coronavirus Disease World Health World Health Organization Organization. World Heal Organ [Internet]. 2020;19(May):2. Available from: https://covid19.who.int/
Asia S. Weekly epidemiological update on COVID-19 - 25 January 2022 Edition 76. 25 January 2022. 2022;(January):22. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2022
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1).
Mahdi BA, Suryantoro SD, Romadhon PZ, Windradi C, Widiyastuti KN, Novendrianto D, Widiasi ED, Agustin ED, Firdausa S. Convalescent plasma therapy: The early use in moderate to severe COVID-19 patients in hospitals with limited resources. Journal of Tropical and Infectious Disease. 2021;9:3.
Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. medRxiv Prepr Serv Heal Sci [Internet]. 2020;9922:1–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32995801%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7523138
Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis [Internet]. 2020;98:334–46. Available from: https://doi.org/10.1016/j.ijid.2020.06.107
Langhi DM, Santis GC De, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther [Internet]. 2020;42(2):113–5. Available from: https://doi.org/10.1016/j.htct.2020.04.003
Franchini M, Glingani C, Liumbruno GM. Potential mechanisms of action of convalescent plasma in COVID-19. Diagnosis. 2021;8(4):413–20.
Riwu1a AG, Nugaraha J, Dachlan YP. Differences of Interleukin-18 and Interleukin-10 Levels in Pulmonary Rifampicin Resistant dan Rifampicin Sensitive Tuberculosis Patients in Dr. Soetomo Hospital Surabaya
Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends Immunol [Internet]. 2021;42(1):3–5. Available from: https://doi.org/10.1016/j.it.2020.10.012
Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. medRxiv. 2020;
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–42.
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Heal. 2020;8(April):1–6.
Lakbar I, Luque-Paz D, Mege JL, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: A systematic review. PLoS One [Internet]. 2020;15(11 November):1–15. Available from: http://dx.doi.org/10.1371/journal.pone.0241827
Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol [Internet]. 2020;8(10):823–33. Available from: http://dx.doi.org/10.1016/S2213-8587(20)30271-0
Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312–20.
Herman H, Gharini PPR, Dinarti LK. Clinical cardiac manifestations in coronavirus disease 2019 ( COVID-19 ) patients with. 2020;52(3):120–37.
Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020;11(July).
Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodríguez Y, Gallo JE, Salazar-Uribe JC, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118.
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’’ in COVID-19.’ J Infect [Internet]. 2020;80(6):607–13. Available from: https://doi.org/10.1016/j.jinf.2020.03.037
Sewell HF, Agius RM, Kendrick D, Stewart M. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19. BMJ. 2020;370:1–2.
French MA, Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Vol. 25, Respirology. 2020. p. 680–2.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–6.
Aranha C, Patel V, Bhor V, Gogoi D. Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients. J Med Virol. 2021;93(12):6794–
Copyright (c) 2023 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution — You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
